
Eisai’s investigational oncology treatment farletuzumab has failed to reach its primary endpoint in a late-stage trial. Farletuzumab (MORAb-003) did not …
GlaxoSmithKline says it has shut down one of its two manufacturing facilities in India after offering all workers there early …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

